pemetrexed

GPTKB entity

Statements (61)
Predicate Object
gptkbp:instance_of gptkb:drug
gptkbp:activities inhibits folate metabolism
gptkbp:appointed_by vitamin B12
folic acid
intravenous injection
gptkbp:approves gptkb:2004
gptkb:FDA
gptkbp:availability prescription only
gptkbp:clinical_trial Phase II
Phase III
gptkbp:contraindication severe renal impairment
hypersensitivity to pemetrexed
gptkbp:discovered_by gptkb:Eli_Lilly_and_Company
gptkbp:dosage_form based on renal function
gptkbp:excretion urine
gptkbp:formulation lyophilized powder for injection
gptkbp:frequency every 21 days
https://www.w3.org/2000/01/rdf-schema#label pemetrexed
gptkbp:indication gptkb:malignant_pleural_mesothelioma
non-squamous non-small cell lung cancer
gptkbp:ingredients C20 H22 N8 O6 S
gptkbp:interacts_with other chemotherapy agents
NSAI Ds
gptkbp:invention patented
generic available
gptkbp:is_atype_of L01 B A04
gptkbp:is_used_for treatment of non-small cell lung cancer
treatment of malignant pleural mesothelioma
gptkbp:lifespan 3 to 6 hours
gptkbp:marketed_as gptkb:Alimta
gptkbp:metabolism minimal hepatic metabolism
gptkbp:pharmacokinetics gptkb:fragrance
dose-dependent clearance
gptkbp:population adults
elderly
gptkbp:price high
gptkbp:provides_information_on combination therapy
ASCO guidelines
NCCN guidelines
single-agent therapy
gptkbp:research ongoing clinical trials
retrospective studies
prospective studies
gptkbp:research_focus biomarker identification
resistance mechanisms
combination with immunotherapy
gptkbp:safety_features liver function tests
complete blood count
renal function tests
gptkbp:scholarships gptkb:Educational_Institution
financial assistance programs
gptkbp:side_effect gptkb:fandom
fatigue
nausea
neutropenia
gptkbp:storage room temperature
gptkbp:treatment symptom relief
improved survival rates
gptkbp:type_of 137281-23-3
gptkbp:bfsParent gptkb:Alimta
gptkbp:bfsLayer 4